Varex Imaging Corp (VREX) Financial Ratio Screen

NASDAQ Healthcare United States USD 450M
RATIOS FAIL*
Automated financial screen · activity assessed separately
Varex Imaging Corp (VREX) is potentially non-compliant in the automated ratio model. The company's debt ratio of 35.8% exceeds the 30% MSCI new-inclusion threshold relative to total assets. Varex Imaging Corp operates in the Healthcare sector.

Track VREX screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

VREX financial screening at a glance

RATIOS FAIL*Financial ratios shown separately from business review — not a fatwa
Debt ratio
35.8%
Fail vs 30%
Cash ratio
14.0%
Pass vs 30%
Receivables + cash
28.1%
Pass vs 30%
Impermissible income
1.0%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: September 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria not metAt least one available ratio exceeds its threshold
FTSE/Yasaar-styleFinancial criteria not metAt least one available ratio exceeds its threshold
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodSeptember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. It operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. It sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia. The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from September 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 35.8%
/ 30%
14.0%
/ 30%
28.1%
/ 30%
1.01%
/ 5%
RATIOS FAIL*
FTSE 35.8%
/ 33%
14.0%
/ 33%
28.1%
/ 50%
1.01%
/ 5%
RATIOS FAIL*

Financial Highlights

EPS
$-1.64
P/B Ratio
0.9
EV/EBITDA
7.6
EV: $739M
Revenue
$845M
Growth: 4.9%
Beta
0.9
Average volatility
Current Ratio
3.9

Profitability

Gross Margin 34.2%
Operating Margin 7.3%
Net Margin -7.9%
Return on Equity (ROE) -12.9%
Return on Assets (ROA) 3.6%

Cash Flow & Balance Sheet

Operating Cash Flow$42M
Free Cash Flow$19M
Total Debt$396M
Debt-to-Equity81.8
Current Ratio3.9
Total Assets$1.1B

Price & Trading

Last Close$10.78
50-Day MA$12.83
200-Day MA$11.24
Avg Volume334K
Beta0.9
52-Week Range
$6.76
$14.56

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period September 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About Varex Imaging Corp (VREX)

CEO
Mr. Sunny S. Sanyal
Employees
2,400
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap (listing currency)
USD 450M
Currency
USD

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. It operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. It sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia. The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is Varex Imaging Corp (VREX) halal to invest in?

The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is Varex Imaging Corp's debt ratio?

Varex Imaging Corp's debt ratio is 35.8% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are Varex Imaging Corp's key financial metrics?

Varex Imaging Corp has a market capitalization of USD 450M in its listing currency, and revenue of $845M. The company maintains a gross margin of 34.2% and a net margin of -7.9%. Return on equity stands at -12.9%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: September 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.